SUPN — Supernus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.66bn
- $1.37bn
- $607.52m
- 95
- 51
- 81
- 89
Annual cashflow statement for Supernus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 113 | 127 | 53.4 | 60.7 | 1.32 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 28.6 | 29.3 | 42.5 | 19 | 59.8 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.613 | -36.5 | 3.57 | -22.1 | -9.14 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 143 | 138 | 127 | 117 | 111 |
| Capital Expenditures | -2.74 | -3.45 | -2.04 | -0.412 | -0.551 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -155 | -31.3 | -79.9 | -216 | 269 |
| Acquisition of Business | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -158 | -34.7 | -81.9 | -217 | 269 |
| Financing Cash Flow Items | 0 | 0 | — | -22.9 | -1.99 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.93 | 3.56 | -130 | -10.5 | -398 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.9 | 107 | -85.2 | -110 | -18.1 |